News Merck sets sights on Epstein-Barr virus jab with Opko deal Licensing agreement includes $50m upfront, with a total value of $922.5m, including milestones.
News Growth hormone could be filed without further trials, says O... Drug could be filed after "outlier" analysis.
News OPKO weekly growth hormone jab fails in phase 3 US biotech OPKO Health has said it will continue with clinical development of its long-acting human growth hormone product (hGH-CTP), even though it has failed in a late stage trial in adul
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face